Tech Company Financing Transactions
Ampersand Biomedicines Funding Round
Eli Lilly and Company, Flagship Pioneering and private investors joined a $65 million Series B venture round for Ampersand Biomedicines. The financing round was announced on 3/19/2025.
Transaction Overview
Company Name
Announced On
3/19/2025
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to drive the acceleration of its initial pipeline of programs, including one in immuno-inflammation and another in immuno-oncology, both of which are planned to enter IND-enabling studies in 2025.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
135 William T. Morrissey Blvd
Boston, MA 02125
USA
Boston, MA 02125
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of medicines and body therapeutics designed to act at the site of disease. The company combines a localizing element that enables disease-specific precision with an actuator specifically chosen for disease modification, enabling researchers to navigate a large range of diseases in almost all areas of the body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Noubar Afeyan
Chief Executive Officer
Avak Kahvejian
Chief Technical Officer
Daniel Blom
Browse more venture capital transactions:
Prev: 3/19/2025: Proscia venture capital transaction
Next: 3/19/2025: BioClec venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs